Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response
Abstract
For high-risk prostate cancer, standard treatment options include radical prostatectomy (RP) or radiotherapy plus androgen deprivation therapy (ADT). Despite definitive therapy, many patients will have disease recurrence. Imaging has the potential to better define characteristics of response and resistance. In this study, we evaluated prostate multiparametric MRI (mpMRI) before and after neoadjuvant enzalutamide plus ADT.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 15, 2021
- Source ID
- 10.1158/1078-0432.ccr-20-2344
Entities
People
- Adam G Sowalsky
- Amy Hankin
- Anna Couvillon
- Baris Turkbey
- David J. VanderWeele
- Fatima Karzai
- Guinevere Chun
- Huihui Ye
- James L. Gulley
- Joanna H. Shih
- John R. Bright
- Lisa M. Cordes
- Maria J. Merino
- Marijo Bilusic
- Monique N. Williams
- Nicholas T Terrigino
- Nicole V Carrabba
- Peter A. Pinto
- Peter L Choyke
- Ravi A Madan
- Rosina T Lis
- Scott Wilkinson
- Stephanie A. Harmon
- Stephanie M Walker
- William L. Dahut
Organizations
- Harvard Medical School
- National Cancer Institute
- National Institutes of Health
- UCLA Ronald Reagan Medical Center
- United States Department of Defense